Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

Drug repurposing in pancreatic ductal adenocarcinoma

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Publications

Potential anti-metastatic activity of Imidazoline I1 receptor agonists in pancreatic ductal adenocarcinoma.

Author(s): Zivic K, Pavlovic M, Ostojic M, Srdic-Rajic T, Grahovac J.
Published in: Keystone Symposium “Precision Oncology: Translating Discovery to the Clinic”., 2021
Publisher: Keystone Symposia

Imidazoline-1 receptor agonist reduces cytokine production of PDAC stellate cells

Author(s): Živić K, Ostojić M , Pavlović M, Srdić-Rajić T, Grahovac J.
Published in: EACR2022 Annual congress abstract book, 2022
Publisher: EACR

Nischarin agonist rilmenidine inhibits pancreatic ductal adenocarcinoma cell migration and invasion (opens in new window)

Author(s): Marijana Pavlovic, Marija Ostojic, Kristina Zivic, Aleksandar Pavic, Tatjana Srdic-Rajic, Jelena Grahovac
Published in: Cancer Research, Issue Volume 82 12_Supplement, 2022, Page(s) 3463-3463
Publisher: The American Association for Cancer Research
DOI: 10.1158/1538-7445.am2022-3463

Rilmenidine binds to and inhibits the activity of MDR pumps in pancreatic ductal adenocarcinoma

Author(s): Ostojić M, Đurić A, Srdić-Rajić T, Dobričić V, Grahovac J.
Published in: 5th Annual meeting of the CA17104 Abstract book, 2022
Publisher: University of Coimbra

Nischarin is expressed in pancreatic ductal adenocarcinoma and is a potential target for drug repurposing (opens in new window)

Author(s): Jelena Grahovac, Marijana Pavlovic, Marija Ostojic, Kristina Zivic, Daniel Galun and Tatjana Srdic-Rajic
Published in: Cancer Research, Issue Volume 81 22_Supplement, 2021
Publisher: American Association for Cancer Research
DOI: 10.1158/1538-7445.panca21-po-040

Anti-migratory properties of Nischarin agonist rilmenidine in pancreatic ductal adenocarcinoma.

Author(s): Živić K, Ostojić M, Pavlović M, Srdić-Rajić T, Grahovac J.
Published in: Proceedings of the Tenth Conference of the Serbian Biochemical Society, 2021, Page(s) 192
Publisher: Faculty of Chemistry, University of BElgrade

Nischarin as a target for drug repurposing in solid tumors.

Author(s): Ostojic M, Pavlovic M, Zivic K, Srdic-Rajic T, Grahovac J
Published in: EACR2021 conference proceedings, 2021
Publisher: EACR

I1 imidazoline receptor ligand inhibits P-glycoprotein efflux in pancreatic ductal adenocarcinoma cells

Author(s): Ostojić M, Srdić-Rajić T, Pavlović M, Živić K, Grahovac J.
Published in: 5th Congress of SDIR: Translational potential of cancer research in Serbia Abstract book, 2021
Publisher: SDIR

Nischarin is expressed in pancreatic ductal adenocarcinoma and is a potential target for drug repurposing

Author(s): Jelena Grahovac
Published in: 5th annual meeting of the COST-1704 Abstract book, 2021
Publisher: STRATAGEM

Drug repurposing in pancreatic ductal adenocarcinoma

Author(s): Jelena Grahovac
Published in: 5th Congress of SDIR: Translational potential of cancer research in Serbia Abstract book, 2021, Page(s) p6
Publisher: SDIR

Potential anti-MDR effect of rilmenidine in pancreatic ductal adenocarcinoma.

Author(s): Ostojić M, Srdić-Rajić T, Pavlović M, Živić K, Grahovac J
Published in: EACR Conference Goodbye Flat Biology: Next Generation Cancer Models Abstract book, 2021
Publisher: EACR

Nischarin expression may have differing roles in male and female melanoma patients (opens in new window)

Author(s): Marija Ostojić, Marko Jevrić, Olivera Mitrović-Ajtić, Miljana Tanić, Milena Čavić, Tatjana Srdić-Rajić Jelena Grahovac
Published in: Research Square, 2022
Publisher: Research Square
DOI: 10.21203/rs.3.rs-1576440/v2

Searching for OpenAIRE data...

There was an error trying to search data from OpenAIRE

No results available

My booklet 0 0